CoChat

Perspectives on low-density-lipoprotein cholesterol goal achievement

Catapano, Alberico L. · 2009 · Current Medical Research and Opinion

The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with an increased risk of coronary heart disease (CHD). European and US guidelines now recommend lower LDL-C levels, particularly in high-risk patients. Although LDL-C treatment goals to reduce the risk of CHD are clear, many patients do not reach their LDL-C goals. OBJECTIVES: Examine consensus guideline targets for LDL-C lowering in patients at high or very high cardiovascular risk; examine cholesterol goal achievement in clinical practice; evaluate the effectiveness of ezetimibe/statin and other adjunctive lipid-lowering treatments in achieving LDL-C goals; and consider ongoing controversies and the randomized controlled trials that may help to resolve or better illuminate them. METHODS: An English-language PubMed search was conducted to identify prospective randomized controlled trials, open-label studies, and retrospective and observational studies from 2001 (same year that the executive summary of the National Cholesterol Education Program's Adult Treatment Panel III was published) to present for an analysis of the effects of adjunctive therapies on LDL-C lowering and goal attainment in patients at elevated cardiovascular risk. RESULTS: Elevated LDL-C is the primary target of lipid-lowering therapy; aggressive lowering is of great benefit to those at high risk. Statins are recommended first-line lipid-lowering agents, with a long, well-regarded history of efficacy and safety. Not all patients, however, can achieve recommended LDL-C goals simply using starting doses of statins. For such patients, more intensive therapy utilizing high-dose statins or combination therapy, including statins combined with other lipid-lowering agents, such as ezetimibe, bile acid resins (BARs), or niacin, is warranted. Potential limitations of the present review include possible publication bias and the focus on pharmacotherapy rather than lifestyle modification and the important objective of multiple risk-factor modification to reduce absolute global cardiovascular risk. CONCLUSIONS: With a well-established link between elevated LDL-C and cardiovascular risk, aggressive LDL-C lowering becomes particularly important. Patients needing intensive LDL-C lowering to achieve goals will often require adjunctive treatments, including ezetimibe, BARs, or niacin along with statins. Given both their high mg: mg potency in lowering LDL-C and favorable tolerability and patient acceptance/adherence profile, ezetimibe/statin combination regimens arguably provide the greatest likelihood for patients to reach new, lower LDL-C targets; however, efficacy and safety data of any adjunctive treatment, along with drug costs and patient adherence to treatment (partly related to complexity of the regimen) all need to be considered when determining the optimal regimen to achieve LDL-C goals in individual patients according to their baseline absolute cardiovascular risk, LDL-C level, and consensus LDL-C targets.

Overview

Integrity signals

Registry

Crossref · 10.1185/03007990802631438

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 96 references

Research works printed but not linked: 8

  1. Scandinavian Simvastatin Survival Study Group, 1994, Lancet, 344, 1383
  2. Downs J, 1998, Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279, 1615
  3. 10.1001/jama.257.16.2176 · doi:10.1001/jama.257.16.2176 · Paper page
  4. Stamler J, 1986, Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA, 256, 2823
  5. Gaddi A, 2007, Vasc Health Risk Manag, 3, 877
  6. 2005, Heart, 9, 1
  7. Laforest L, 2007, Presented at European Society of Cardiology
  8. Lipid Research Clinics, 1984, The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA, 251, 365

Cited by

See all 40

Metadata

Authors
Catapano, A. L.
Affiliations
University of Milan (IT)
Corresponding author
Catapano, Alberico L.
Venue
Current Medical Research and Opinion
Published
2008-12-23
Volume
25
Issue
2
Pages
431-447
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2066666645
Cited by
40
References
97
Citations by year
2020: 2 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 3 · 2012: 4
FWCI
1.02
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
cholesterol, LDL-C goal attainment, statins, ezetimibe, nicotinic acid, lipid-lowering therapy, high cardiovascular risk, coronary artery disease, APOE ε4, medication adherence, combination therapy, cardiovascular risk reduction
MeSH terms
Anticholesteremic Agents, Drug Therapy, Combination, Europe, United Kingdom, Humans, Cholesterol, LDL, United States, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Perspectives on low-density-lipoprotein cholesterol goal achievement. https://app.cochat.ai/papers/10.1185/03007990802631438
The paper
Catapano, A. L. (2009). Perspectives on low-density-lipoprotein cholesterol goal achievement. Current Medical Research and Opinion. https://doi.org/10.1185/03007990802631438

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.